Christian Kurzeder

6.5k total citations · 1 hit paper
88 papers, 2.0k citations indexed

About

Christian Kurzeder is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Christian Kurzeder has authored 88 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Reproductive Medicine, 32 papers in Oncology and 26 papers in Surgery. Recurrent topics in Christian Kurzeder's work include Ovarian cancer diagnosis and treatment (51 papers), Endometrial and Cervical Cancer Treatments (20 papers) and Intraperitoneal and Appendiceal Malignancies (17 papers). Christian Kurzeder is often cited by papers focused on Ovarian cancer diagnosis and treatment (51 papers), Endometrial and Cervical Cancer Treatments (20 papers) and Intraperitoneal and Appendiceal Malignancies (17 papers). Christian Kurzeder collaborates with scholars based in Germany, Switzerland and France. Christian Kurzeder's co-authors include Philipp Harter, Andreas du Bois, Jalid Sehouli, Pauline Wimberger, R. Kreienberg, Florian Heitz, Ivo Meinhold‐Heerlein, Alexander Mustea, Christina Fotopoulou and William P. Weber and has published in prestigious journals such as Nature, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Christian Kurzeder

80 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy

2021 208 citations Ana Luísa Correia, Joao C. Guimaraes et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christian Kurzeder Germany	25	1.0k	709	589	494	363	88	2.0k
Shoji Kodama Japan	20	1.5k 1.4×	806 1.1×	473 0.8×	900 1.8×	474 1.3×	40	2.6k
Dominique Berton-Rigaud France	18	655 0.6×	1.0k 1.4×	246 0.4×	405 0.8×	217 0.6×	73	1.8k
Wataru Yamagami Japan	24	703 0.7×	641 0.9×	212 0.4×	763 1.5×	473 1.3×	124	2.0k
Eliane Mery-Lamarche France	23	431 0.4×	579 0.8×	421 0.7×	587 1.2×	333 0.9×	64	1.7k
Jennifer L. Santos Canada	13	1.3k 1.2×	416 0.6×	277 0.5×	558 1.1×	809 2.2×	21	2.0k
Tsunehisa Kaku Japan	30	1.1k 1.0×	454 0.6×	425 0.7×	1.3k 2.6×	512 1.4×	107	2.5k
Gabriella Parma Italy	19	869 0.8×	617 0.9×	350 0.6×	596 1.2×	296 0.8×	53	1.6k
Yoshihiro Ohishi Japan	24	594 0.6×	491 0.7×	327 0.6×	459 0.9×	529 1.5×	84	1.7k
Leah Prentice Canada	18	1.0k 1.0×	552 0.8×	220 0.4×	540 1.1×	909 2.5×	26	2.2k
Arto Leminen Finland	28	590 0.6×	538 0.8×	260 0.4×	651 1.3×	415 1.1×	60	1.9k

Countries citing papers authored by Christian Kurzeder

Since Specialization

Citations

This map shows the geographic impact of Christian Kurzeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Kurzeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Kurzeder more than expected).

Fields of papers citing papers by Christian Kurzeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Kurzeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Kurzeder. The network helps show where Christian Kurzeder may publish in the future.

Co-authorship network of co-authors of Christian Kurzeder

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Kurzeder. A scholar is included among the top collaborators of Christian Kurzeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Kurzeder. Christian Kurzeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heidinger, Martin, Florian S. Halbeisen, Fabienne D. Schwab, et al.. (2025). Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes. The Breast. 85. 104641–104641.

Heidinger, Martin, Ricardo Coelho, Fabienne D. Schwab, et al.. (2025). TP53 Mutations and Phosphatidylinositol 3-Kinase/AKT Pathway Alterations Are Key Determinants of Breast Cancer Outcome Independent of Subtype and Stage. JCO Precision Oncology. 9(9). e2400767–e2400767.

Marmé, Frederik, Philipp Harter, Andrés Redondo, et al.. (2024). Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.. Journal of Clinical Oncology. 42(17_suppl). LBA5501–LBA5501. 9 indexed citations

Fidalgo, José Alejandro Pérez, Barbara Schmalfeldt, Angela George, et al.. (2024). Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer. International Journal of Gynecological Cancer. 35(7). 101863–101863.

Oseledchyk, Anton, et al.. (2023). Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx. Diagnostics. 14(1). 97–97. 1 indexed citations

Kuhar, Cvetka Grašič, et al.. (2023). Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population. Radiology and Oncology. 57(2). 211–219. 2 indexed citations

Correia, Ana Luísa, Joao C. Guimaraes, Priska Auf der Maur, et al.. (2021). Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 594(7864). 566–571. 208 indexed citations breakdown →

Colomban, Olivier, Michel Tod, Alexandra Léary, et al.. (2019). Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research. 25(17). 5342–5350. 37 indexed citations

Montagna, Giacomo, Andres R. Schneeberger, Lorenzo Rossi, et al.. (2019). The impact of depression on adherence to organized and opportunistic breast cancer screening. European Journal of Cancer Prevention. 29(1). 53–59. 4 indexed citations

10.

Weber, William P., Savas D. Soysal, Jasmin Zeindler, et al.. (2017). Current standards in oncoplastic breast conserving surgery. The Breast. 34. S78–S81. 17 indexed citations

11.

Meinhold‐Heerlein, Ivo, Christina Fotopoulou, Philipp Harter, et al.. (2016). The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Archives of Gynecology and Obstetrics. 293(4). 695–700. 172 indexed citations

12.

Kurzeder, Christian, Isabel Bover, Frederik Marmé, et al.. (2015). Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 5504–5504. 5 indexed citations

13.

Harter, Philipp, Pier Francesco Alesina, Dietmar Lorenz, et al.. (2014). Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecologic Oncology. 132(3). 537–541. 33 indexed citations

14.

Hilpert, Felix, Christian Kurzeder, Barbara Schmalfeldt, et al.. (2014). Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8). Geburtshilfe und Frauenheilkunde. 74(S 01). 1 indexed citations

15.

Hasegawa, Kosei, Shoji Nagao, Masanori Yasuda, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. International Journal of Gynecological Cancer. 24(9 Suppl 3). S90–S95. 44 indexed citations

16.

Emons, Guenter, Christian Kurzeder, Barbara Schmalfeldt, et al.. (2014). Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).. Journal of Clinical Oncology. 32(15_suppl). 5565–5565. 2 indexed citations

17.

Heitz, Florian, Philipp Harter, Jana Barinoff, et al.. (2012). Bevacizumab in the Treatment of Ovarian Cancer. Advances in Therapy. 29(9). 723–735. 32 indexed citations

18.

Baumann, Klaus, Andreas du Bois, Werner Meier, et al.. (2012). A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology. 23(9). 2265–2271. 67 indexed citations

19.

Hancke, Katharina, Michael Denkinger, J. König, et al.. (2009). Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Annals of Oncology. 21(4). 748–753. 83 indexed citations

20.

Loibl, Sibylle, Jacobus Pfisterer, Pauline Wimberger, et al.. (2007). 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. European Journal of Cancer Supplements. 5(4). 312–312. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact